CORRECTION

Correction: METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression

Wei Wei^{1,2}, Zhong-Yuan Zhang³, Bin Shi⁴, Yike Cai⁵, Hou-Shun Zhang⁶, Chun-Lei Sun⁴, Yun-Fei Fei^{1,2}, Wen Zhong⁶, Shuang Zhang^{1,2}, Chen Wang^{1,2}, Bing He^{1,2}, Guan-Min Jiang^{7*} and Hao Wang^{1,2*}

Correction: J Exp Clin Cancer Res 42, 151 (2023) https://doi.org/10.1186/s13046-023-02732-y

Following publication of the original article [1], the authors would spotted errors in the affiliations. 'The First Affiliated Hospital of USTC' should come before the division. Affiliations 1, 3, 4, and 6 were corrected accordingly.

The corrections do not affect the overall result or conclusion of the article. The original article has been corrected.

The online version of the original article can be found at https://doi. org/10.1186/s13046-023-02732-y.

*Correspondence:

Guan-Min Jiang jianggm3@mail.sysu.edu.cn

Hao Wang

demo@ustc.edu.cn

¹Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

²Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, China

³Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

⁴Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and

Technology of China, Hefei, China

⁵Center for Certification and Evaluation, Guangdong Drug Administration, Guangzhou, China

⁶Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

⁷Department of Clinical Laboratory, The Fifth Affiliated Hospital, Sun Yatsen University, Zhuhai, China

Wei W, Zhang ZY, Shi B, et al. METTL16 promotes glycolytic metabolism 1. reprogramming and colorectal cancer progression. J Exp Clin Cancer Res. 2023;42:151. https://doi.org/10.1186/s13046-023-02732-y.

Publisher's Note

Reference

Published online: 22 January 2024

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Wei et al. Journal of Experimental & Clinical Cancer Research https://doi.org/10.1186/s13046-024-02951-x





(2024) 43:26

